Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09
Nunn A et al. – The development of effective microbicide products remains one of the strongest hopes for new biomedical prevention tools. MDP301 is the largest Phase III microbicide trial to date, with 9404 enrolments, and is scheduled for completion in September 2009. Results are expected towards the end of 2009.
Related Articles
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
Relevance Score: 95%
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Relevance Score: 95%
Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09
Relevance Score: 94%
Sperm May Play Leading Role In Spreading HIV
ScienceDaily, 10/27/09
Relevance Score: 94%
Female sex work and HIV risks in Croatia
AIDS Care, 10/29/09
Relevance Score: 93%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Results from two Phase II trials add to understanding of ticagrelor and how it works in the body
AstraZeneca, 11/19/09
Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
Genzyme, 11/19/09
Sponsor
Article Search
Sponsor


See Latest Articles


